IB
IBRX.US Immunitybio Inc
- Market cap
- USD 6.40B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IBRX.US undervalued?
Graham numberThe Graham number of Immunitybio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immunitybio Inc fundamental analysis
No fundamental analysis for Immunitybio Inc yet.
Immunitybio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immunitybio Inc
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic ag…
Full company profileImmunitybio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immunitybio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 44.0K | 45.0K | 47.0K | 43.0K | 605K | 934K | 240K | 622K | 14.7M | 113M | 192M |
| Gross Profit | 44.0K | 45.0K | 3.16M | -8.97M | 605K | 934K | 240K | 622K | 14.7M | 113M | 190M |
| Operating Income | -125M | -99.1M | -98.4M | -66.9M | -221M | -330M | -351M | -362M | -344M | -256M | -279M |
| EBITDA | -118M | -90.7M | -86.7M | -51.8M | -204M | -321M | -352M | -479M | -264M | -224M | -1.30B |
| Net Income | -121M | -96.4M | -96.2M | -65.8M | -222M | -347M | -417M | -583M | -414M | -351M | -1.40B |
| EPS | -0.37 | -0.30 | -0.30 | -0.17 | -0.58 | -0.89 | -1.04 | -1.15 | -0.59 | -0.38 | -1.32 |
| Balance Sheet | |||||||||||
| Total Assets | 317M | 250M | 182M | 143M | 221M | 469M | 362M | 504M | 383M | 502M | 609M |
| Total Liabilities | 24.1M | 31.6M | 35.9M | 22.4M | 340M | 713M | 812M | 1.09B | 871M | 1.00B | 1.75B |
| Shareholders' Equity | 293M | 219M | 146M | 121M | -120M | -242M | -447M | -587M | -489M | -500M | -1.15B |
| Cash & Short-term Investments | 199M | 128M | 74.1M | 51.7M | 96.1M | 317M | 107M | 266M | 150M | 243M | 334M |
| Total Debt | 8.21M | 7.27M | 6.91M | 14.8M | 276M | 646M | 724M | 727M | 504M | 878M | 870M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -38.6M | -48.8M | -63.4M | -152M | -172M | -274M | -338M | -367M | -391M | -305M | -290M |
| Capital Expenditure | 6.56M | 34.8M | 13.1M | 4.29M | 1.67M | 33.6M | 78.2M | 30.6M | 6.89M | 3.85M | 11.0M |
| Free Cash Flow | -45.2M | -83.6M | -76.5M | -156M | -173M | -308M | -416M | -397M | -398M | -309M | -301M |
| Ratios | |||||||||||
| ROE | -41.2% | -44.1% | -65.9% | -54.5% | - | - | - | - | - | - | - |
| ROA | -38.1% | -38.5% | -52.9% | -46.0% | -100.2% | -74.0% | -115.0% | -115.6% | -108.0% | -70.0% | -229.2% |
| Net Profit Margin | -274,565.9% | -214,273.3% | -204,736.2% | -152,997.7% | -36,669.6% | -37,129.6% | -173,569.6% | -93,761.4% | -2,804.8% | -310.2% | -726.1% |
| Debt to Equity | 0.03x | 0.03x | 0.05x | 0.12x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immunitybio Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 616K | 0.00 | - |
| 2021 | USD 334M | 0.86 | - |
| 2020 | USD 4.44M | 0.01 | - |
| 2019 | USD 2.28M | 0.01 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Immunitybio Inc
- Insiders 62.13%
- Institutions 20.47%
- Public & others 17.40%
- Shares outstanding 1.06B
- Free float 411M
Top funds holding IBRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 13.5M | 1.27% | +16.30% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 12.6M | 1.18% | +2.68% | Oct 2026 |
| iShares Russell 2000 ETF | 9.80M | 0.92% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 9.55M | 0.90% | +13.26% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 5.24M | 0.49% | +8.64% | Sep 2026 |
| Fidelity Small Cap Index | 4.23M | 0.40% | +0.15% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 3.62M | 0.34% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 3.06M | 0.29% | -0.19% | Oct 2026 |
| SEB Läkemedelsfond A (SEK) | 2.45M | 0.23% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 2.25M | 0.21% | +1.13% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 2.14M | 0.20% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 1.84M | 0.17% | +16.33% | Sep 2026 |
| Principal US Small Cap ETF | 1.67M | 0.16% | +0.05% | Oct 2026 |
| Schwab US Mid-Cap ETF | 1.22M | 0.11% | +0.13% | Oct 2026 |
| Bridge Builder Small Cap Fund | 1.13M | 0.11% | +80.30% | Oct 2026 |
| Vanguard Health Care ETF | 1.12M | 0.11% | +0.12% | Sep 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 1.09M | 0.10% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 939K | 0.09% | -0.37% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 904K | 0.09% | +0.20% | Oct 2026 |
| Trenchless Fund ETF | 899K | 0.08% | 0.00% | Oct 2026 |
Top institutions holding IBRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 34.1M | 3.20% | +29.37% | Jun 2026 |
| State Street Corp | 21.4M | 2.01% | +20.84% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 17.9M | 1.68% | +9.44% | Jun 2026 |
| Vanguard Capital Management, LLC | 15.7M | 1.48% | +3.73% | Jun 2026 |
| D. E. Shaw & Co LP | 11.6M | 1.09% | -8.12% | Jun 2026 |
| Two Sigma Investments LLC | 11.1M | 1.04% | +153.04% | Jun 2026 |
| Geode Capital Management, LLC | 9.85M | 0.93% | +22.61% | Jun 2026 |
| Millennium Management LLC | 5.58M | 0.52% | +292.88% | Jun 2026 |
| Northern Trust Corp | 3.57M | 0.34% | +42.34% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.43M | 0.32% | -14.59% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.23M | 0.30% | -0.09% | Jun 2026 |
| UBS Group AG | 3.20M | 0.30% | +8.52% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.89M | 0.27% | +16.57% | Jun 2026 |
| Woodline Partners LP | 2.50M | 0.24% | -27.48% | Jun 2026 |
| SEB Asset Management AB | 2.45M | 0.23% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 2.41M | 0.23% | +13.62% | Jun 2026 |
| Bank of America Corp | 2.18M | 0.21% | -10.76% | Jun 2026 |
| Principal Financial Group Inc | 1.74M | 0.16% | +5,779.03% | Sep 2026 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.72M | 0.16% | -41.18% | Jun 2026 |
| Federated Hermes Inc | 1.71M | 0.16% | +23.55% | Jun 2026 |
Immunitybio Inc company profile
- Company name
- Immunitybio Inc
- Ticker
- IBRX.US
- Exchange
- USA Stocks
- Listed since
- Jul 28, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 684
- Fiscal year end
- December
- Address
- 3530 John Hopkins Court, San Diego, CA, United States, 92121
- Phone
- 844 696 5235
- Website
- immunitybio.com
About Immunitybio Inc
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Immunitybio Inc management
10- Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc.Founder, Executive Chairman and Global Chief Scientific & Medical Officer · born 1953
- Mr. Richard Gerald AdcockPresident, CEO & Director · born 1969
- Mr. David C. SachsChief Financial Officer · born 1978
- Ms. Regan J. LauerChief Accounting Officer · born 1970
- Dr. Barry J. Simon M.D.Chief Corporate Affairs Officer & Director · born 1965
- Dr. Enrique Diloné Ph.D., RACChief Technology Officer · born 1967
- Ms. Sarah SingletonChief Communications Officer & Head of Patient Advocacy
- Ms. Emily ArisonSenior Vice President of Human Resources
- Dr. Leonard S. Sender M.D.Chief Medical Officer of Liquid Tumors & Cell Therapy
- Dr. Sandeep K. Reddy M.D.Chief Medical Officer